Cukurova Score Validation Study
Conditions: Epithelial Ovarian Cancer; Primary Cytoreduction Sponsors: Cukurova University; Mu ğla Sıtkı Koçman University; Sakarya University; Gazi University; Ankara Etlik City Hospital; Kayseri City Hospital; Mersin University; Selçuk University; Bezmialem Vakif University; Uludag University; Mersin City Hospital; Marmara University; Prof. Dr. Cemil Tascıoglu City Hospital; Ankara Un iversity; Ege University; Hacettepe University; Akdeniz University; Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital; Mustafa Kemal University; Trakya University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 23, 2024 Category: Research Source Type: clinical trials
PPOS vs GnRH Antagonist in Ovarian Stimulation (ProGanOS Study)
Conditions: Progestins Primed Ovarian Stimulation Interventions: Drug: Dydrogesterone 10 mg; Drug: Cetrorelix 0.25 mg Sponsors: M ỹ Đức Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial)
Conditions: Ovarian Cancer Interventions: Drug: Bevacizumab; Drug: Olaparib Sponsors: Vall d ' Hebron Institute of Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies
Conditions: Cancer, Ovarian; Chemotherapy Effect; Calorie Deficiency; Fasting, Intermittent Interventions: Other: Fasting Mimicking Diet; Drug: Chemotherapy Sponsors: L-Nutra Inc; University of Tennessee Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
Conditions: Ovarian Cancer; Lung Cancer Interventions: Drug: [68Ga]Ga-EVS459; Drug: [177Lu]Lu-EVS459 Sponsors: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Letrozole Alone Protocol Versus Using Letrozole and HCG Protocol
Conditions: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries Interventions: Drug: Letrozole tablets Sponsors: Egymedicalpedia Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy in Recurrent Epithelial Ovarian Cancer
Conditions: Ovarian Cancer Interventions: Biological: Innocell Autologous Cellular Immunotherapy Sponsors: PhotonPharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
Diagnosis of Epithelial Ovarian Cancer Using Ovarian Cancer Score (OCS) Test
Conditions: Epithelial Ovarian Cancer; Adnexal Mass Sponsors: Chongqing University Cancer Hospital; Zhejiang Cancer Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; The First Affiliated Hospital of Zhengzhou University; 3D Medicines Corporation Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Conditions: Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive Interventions: Drug: Mirvetuximab Soravtansine; Drug: Lubricating Eye Drops; Drug: Prednisolone acetate ophthalmic suspension 1% eye drops; Drug: Brimonidine tartrate ophthalmic solution eye drops Sponsors: ImmunoGen, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
OCALA, Fla., April 10, 2024— AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the treatment of recurrent... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 10, 2024 Category: Pharmaceuticals Source Type: clinical trials
Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant.
Conditions: Primary Ovarian Insufficiency; Hypogonadotropic Hypogonadism; Hormone Replacement Therapy Sponsors: University of Colorado, Denver Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Visceral Adiposity Index Differences Between Subtypes of Polycystic Ovary Syndrome
Conditions: Visceral Adiposity Index; Polycystic Ovary Syndrome Sponsors: U şak University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Impact of Different Hemostasis Methods on Ovarian Function and Fertility During Laparoscopic Ovarian Cystectomy of Benign Ovarian Cyst
Conditions: Ovarian Cyst Benign Interventions: Combination Product: the absorbable hemostat and suture; Combination Product: electrocoagulation and suture; Other: suture Sponsors: West China Second University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
Screening for Ovarian Malignancy
Conditions: Early Detection of Ovarian Cancer Interventions: Diagnostic Test: Assesment of Different NEoplasias in the adenexa model; Diagnostic Test: Risk of malignancy index; Diagnostic Test: Histopathologic examination Sponsors: Ain Shams Maternity Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients With Platinum-Resistant Ovarian Cancer
BASKING RIDGE, N.J.& RAHWAY, N.J., April 3, 2024– Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the first patient has been dosed in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 3, 2024 Category: Pharmaceuticals Source Type: clinical trials
